Resistance training protected muscle — and its mitochondria — in liver-disease sarcopenia — in mice

Sarcopenia — the loss of muscle mass and strength — is a common and dangerous complication of chronic cholestatic liver disease (CCLD), the group of conditions in which bile flow from the liver is impaired. Muscle in these patients is not just shrinking; its mitochondria are disordered, its protein-breakdown systems are switched on, and its growth signaling is dimmed. A study published October 13, 2026 in Scientific Reports (Cabello-Verrugio, Valero-Breton, Tacchi and colleagues, Universidad Andrés Bello, Chile) asked whether the oldest muscle medicine there is — resistance training — could interrupt that process.

How was it tested?

Male mice were fed a diet containing a hepatotoxin (DDC) for six weeks to induce CCLD-related sarcopenia, while performing a resistance-training program. The researchers then measured strength, muscle mass and physical performance, and examined the muscle in depth: fiber size, internal structure, mitochondrial shape and density, the dynamics proteins that govern mitochondrial fusion and fission (DRP-1, mitofusin-2, OPA-1), the mitochondrial biogenesis regulator PGC-1α, oxygen consumption, breakdown markers, and mTOR growth signaling.

What did training preserve?

Trained mice kept markedly more strength, mass, and performance than sedentary mice with the same liver disease. Their muscle fibers stayed larger, sarcomere proteins were protected, and ultrastructure held up. On the mitochondrial side, training preserved mitochondrial density and dynamics, PGC-1α levels, and oxygen consumption — the muscle's energy system stayed closer to normal. Breakdown signals (MuRF-1, atrogin-1, and autophagy markers) were normalized rather than ramped up, and mTOR phosphorylation — a green light for building protein — was restored.

In plain terms: the disease pushed muscle toward demolition and energy failure on several fronts at once, and training pushed back on essentially all of them.

What does this mean for people with liver disease?

Directly, nothing yet — this is a mouse study, and mouse muscle, mouse livers, and six-week timelines do not prescribe human exercise programs. Indirectly, it strengthens the biological case that structured resistance training deserves proper clinical trials in CCLD-related sarcopenia, a condition with few good options, and it maps the mitochondrial mechanisms such trials should measure.

Anyone with chronic liver disease should treat exercise changes as a medical decision made with their care team; advanced liver disease carries risks (including portal hypertension considerations) that a mouse study cannot speak to. The honest headline is the one on this article: protective in mice, promising for humans, unproven in patients.

Where the evidence stands

• Established: Sarcopenia is a serious complication of chronic cholestatic liver disease and involves proteolytic-system activation, impaired mitochondrial dynamics, and reduced mTOR signaling; resistance training benefits age-related sarcopenia.
• Preliminary: In a 6-week mouse model, resistance training prevented CCLD-induced sarcopenia: preserved strength, fiber size, mitochondrial density/dynamics (DRP-1, MFN2, OPA-1), PGC-1α and oxygen consumption, normalized breakdown markers, and restored mTOR phosphorylation.
• Absent: Any human trial of resistance training for CCLD-related sarcopenia, human dosing (program design) guidance, and safety data in patients with advanced liver disease.